참고문헌
- Arian ER, Pascale F, Anne TN, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.Trends in Pharmacological Sciences, 2, 126-35.
- Baserga R (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res, 55, 249-52.
- Barakat RR, Grisby PW, Sabbatini. Corpus: epithelial tumor (2007). In: Hoskin WJ, Perez CA, Young RC principles and practice of gynecologic oncology, 2rd. Lippincott Williams & Wilkins, Philadelphia, 919-59.
- Bershtein LM (2014). Endometrial cancer, estrogens and metabolic syndrome: scenario becomes more complicated. Vopr Onkol, 3, 254-62.
- Casamassima A, Rozengurt E (1998). Insulin-like growth factor I stimulates tyrosine phosphorylation of p130 (Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3'-kinase and formation of a p130 (Cas). Crk complex. J Biol Chem, 273, 26149-56. https://doi.org/10.1074/jbc.273.40.26149
- Creighton CJ, Casa A, Lazard Z, et al (2008). Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis, J Clin Oncol, 25, 4078-85.
- Derynck R, Goeddel DV, Ullrich A, et al (1987). Synthesis of messenger RNAs for transforminggrowth factors a and b and the epidermal growth factor receptor by human tumors. Cancer Res, 47, 707-12.
- Eugenio M, Giuseppe L, Giuseppe V, et al (1999). Insulinlike growth factor-1 expression in normal and diseased endometrium. Int J Cancer, 80, 188-93. https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<188::AID-IJC5>3.0.CO;2-E
- Gunter MJ, Hoover DR, Yu H, et al (2008). A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev, 4, 921-9.
- Goustin AS, Leof EB, Shipley GD, et al (1986). Growth factors and cancer. Cancer Res, 46, 1015-29.
- Goodwin PJ, Pritchard KI, Ennis M, et al (2008). Insulinlowering effects of metformin in women with early breast cancer. Clin Breast Cancer, 8, 501-5. https://doi.org/10.3816/CBC.2008.n.060
- Haining RE, Schofield JP, Jones DS, et al (1991). Identification of mRNA for epidermal growth factor and transforming growth factor-alpha present in low copy number in human endometrium and decidua using reverse transcriptasepolymerase chain reaction. J Mol Endocrinol, 6, 207-14. https://doi.org/10.1677/jme.0.0060207
- Hirano S, Ito N, Takahashi S, et al (2004). Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol, 25, 187-91.
- Kisfalvi K, Eibl G, Sinnett-Smith J, et al (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res, 69, 6539-45. https://doi.org/10.1158/0008-5472.CAN-09-0418
- Lelle' RJ, Talavera F, Gretz HG, et al (1993). Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer, 72, 519 -25. https://doi.org/10.1002/1097-0142(19930715)72:2<519::AID-CNCR2820720231>3.0.CO;2-#
- Lukanov A, Zeleniuch- Jacquotte A, Lundin E, et al (2004). Prediag no st ic level o f C- peptide, IGF- 1, IGFBP- 1, - 2 and- 3 and r isk o f endometr ial cancer. Int J Cancer, 2, 262-8.
- Lacey JV Jr, Potischman N, Madigan MP, et al (2004). Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev, 4, 607-12.
- Luo Z, Zang M, Guo W (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6, 457-70. https://doi.org/10.2217/fon.09.174
- Liu B, Fan Z, Edgerton SM, et al (2011). Potent anti- proliferative effects of metformin on trastuzumab- resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle, 10, 2959-66. https://doi.org/10.4161/cc.10.17.16359
- Leone A, Di Gennaro E, Bruzzese F, et al (2014). New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res, 159, 355-76. https://doi.org/10.1007/978-3-642-38007-5_21
- Liang K, Qiu S, Lu Y (2014). Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther, 1, 89-98.
- Morrow CP, Curtin JP, Townsend DE (1993). Tumors of the endometrium, in Synopsis of Gynecologic Oncology, 4th ed., New York, NY: Churchill Livingstone, 209.
- Morrison KB, Tognon CE, Garnett MJ, et al (2002). ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene, 21, 5684-95. https://doi.org/10.1038/sj.onc.1205669
- Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, et al (2010). Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell cycle, 9, 1057-64. https://doi.org/10.4161/cc.9.6.10994
- Markowska A, Pawalowska M, Filas V, et al (2014). Does Metformin affect ER, PR, IGF-1R, beta-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol Metab Syndr, 1, 76.
- Nathan DM, Buse JB, Davidson MB, et al (2009). Medical management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy-A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 52, 17-30. https://doi.org/10.1007/s00125-008-1157-y
- Nevadunsky NS, Van Arsdale A, Strickler HD, et al (2014). Metformin use and endometrial cancer survival. Gynecol Oncol, 1, 236-40.
- Pearl MP, Talavera F, Gretz HG, et al (1993). Mitogenic activity of growth factors in the human endometrial cancer cell lines HEC 1A and KLE. Gynecol Oncol, 49, 325-32. https://doi.org/10.1006/gyno.1993.1134
- Pavelic Jasminka, Radakovic Branko, Pavelic Kresimir (2007). Insulin-like growth factor -2 and its receptors (IGF-1R and IGF-2R / mannose-6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol, 105, 727-35. https://doi.org/10.1016/j.ygyno.2007.02.012
- Pollak M (2010). Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res, 3, 1060-5. https://doi.org/10.1158/1940-6207.CAPR-10-0175
- Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010). Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res, 16, 2505-11. https://doi.org/10.1158/1078-0432.CCR-09-2229
- Sachdev D, Hartell JS, Lee AV, et al (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem, 279, 5017-24.
- Samani AA, Chevet E, Fallavollita L, et al (2004). Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of thetype 1 insulin-like growth factor receptor. Cancer Res, 64, 3380-5. https://doi.org/10.1158/0008-5472.CAN-03-3780
- Shaw RJ, Lamia KA, Vasquez D, et al (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-6. https://doi.org/10.1126/science.1120781
- Shu SR, Li XM, Yang YB, et al (2011). Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. International Immunopharmacology, 2, 244-9.
- Salani B, Del Rio A, Marini C, et al (2014). Metformin, cancer and glucose metabolism. Endocr Relat Cancer, 6, 461-71.
- Sarkissyan S, Sarkissyan M, Wu Y, et al (2014). IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One, 7, 103534.
- Torng PL, LeeYC, Huang CY, et al (2008). Insulin- like growth factor protein- 3 (IGFBP- 3) act as an invasion- metastas is suppressor in ovarian endometrial carcinoma. Oncogene, 27, 2137-47. https://doi.org/10.1038/sj.onc.1210864
- Weiderpass E, Brismar K, Bellocco R, et al (200\3). Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer, 9, 1697-704.
- Xie Y, Wang YL, Yu L, et al (2011). Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Molec Biol, 126, 113-20. https://doi.org/10.1016/j.jsbmb.2010.12.006
- Xu JN, Zeng C, Zhou Y, et al (2014). Metformin inhibits StAR expression in human endometriotic stromal cells via AMPKmediated disruption of CREB-CRTC2 complex formation. J Clin Endocrinol Metab, 8, 2795-803.
- Zhou J, Dsupin BA, Giudice LC, Bondy CA (1994). Insulinlike growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab, 79, 1723-34.
- Zhou G, Myers R, Li Y, et al (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74. https://doi.org/10.1172/JCI13505
피인용 문헌
- Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6973
- Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines vol.26, pp.7, 2016, https://doi.org/10.1097/IGC.0000000000000761
- Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer vol.26, pp.9, 2016, https://doi.org/10.1097/IGC.0000000000000818
- Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins pp.1473-0766, 2017, https://doi.org/10.1080/09513590.2017.1409708
- Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia vol.50, pp.4, 2018, https://doi.org/10.1007/s11255-018-1826-9
- Metformin as a Therapeutic Target in Endometrial Cancers vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00341